The information of our products contained in this section is partial and for orientation purposes only. A health care professional or certified physician must always be consulted for an appropriate diagnosis and use of these medications.

 BRAND                                                   DRUG SUBSTANCE                                                  PRESENTATION

             DALAM® 15                                                              Midazolam                                                                                        15 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Midazolam
Composition:
 Each tablet contains: Midazolam (as Midazolam maleate) 15 mg.
Therapeutic Action:
 Hypnotic
Indications:
 Short duration treatment for insomnia. Pre-minor surgery procedure anxiety. Anesthetic induction.
Dosage and Administration
Usual Dose in Adults: 15 mg.
Presentation:
 Packages containing 30 grooved, coated tablets.
 
             DOLOFRIX®                                                             Codeine - Paracetamol                                                                    30 mg / 500 mg tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Paracetamol + Codeine
Composition:
 Each tablet contains Paracetamol 500 mg and Codeine Phosphate 30 mg.
Therapeutic Action:
 Potent analgesic, for the systematic treatment of pain.
Indications:
 Treatment of moderate to severe pain.
Dosage and Administration
Orally, one tablet every 4-6 hours according to the intensity of pain and patient tolerance.
Presentation:
 Packages containing 30 tablets.
 
             DOLOFRIX® FORTE                                                Codeine - Paracetamol                                                                    60 mg / 300 mg tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Paracetamol + Codeine
Composition:
 Each tablet contains Paracetamol 300 mg and Codeine Phosphate 60 mg.
Therapeutic Action:
 Potent analgesic, for the systematic treatment of pain.
Indications:
 Treatment of moderate to severe pain.
Dosage and Administration
Orally, one tablet every 4-6 hours according to the intensity of pain and patient tolerance.
Presentation:
 Packages containing 30 tablets.
 
             DONEPES® 5                                                           Donepezil                                                                                          5 mg coat. tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Donepezil Hydrochloride
Composition:
 Each tablet of DONEPES 5 contains Donepezil Hydrochloride 5mg.
Therapeutic Action:
 Selective and reversible acetylcholinesterase inhibitor.
Indications:
 Treatment of mild to moderate dementia of the Alzheimer type.
Dosage and Administration
Starting Dose: 5 mg per day in a single dose. DONEPES must be administered orally at night before going to sleep. The 5 mg dose must be continued for at least a one-month period. It may later be increased to 10 mg/day in a single nightly dose based on the clinical response.
Presentation:
 DONEPES 5: Packages containing 30 coated tablets.
 
             DONEPES® 10                                                         Donepezil                                                                                          10 mg coat. tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Donepezil Hydrochloride
Composition:
 Each tablet of DONEPES 10 contains Donepezil Hydrochloride 10mg.
Therapeutic Action:
 Selective and reversible acetylcholinesterase inhibitor.
Indications:
 Treatment of mild to moderate dementia of the Alzheimer type.
Dosage and Administration
Starting Dose: 5 mg per day in a single dose. DONEPES must be administered orally at night before going to sleep. The 5 mg dose must be continued for at least a one-month period. It may later be increased to 10 mg/day in a single nightly dose based on the clinical response.
Presentation:
 DONEPES 10: Packages containing 30 coated tablets.
 
             MYSTIKA® 25                                                           Pregabalin                                                                                        25 mg tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Pregabalin
Composition:
 Each capsule of Mystika 25 contains Pregabalin 25mg.
Therapeutic Action:
 Antiepileptic. Antineuralgic. Anxiolytic.
Indications:
 Treatment of neuropathic pain in adults. Adjunctive therapy for partial seizures with or without secondary generalization in adults. Treatment of generalized anxiety disorder in adults. Treatment of fibromyalgia.
Dosage and Administration
Orally, initially 25 mg per day. The dose may be increased to 300 mg daily. Maximum dose 600 mg per day.
Presentation:
 Mystika 25: packages containing 30 capsules.
 
             MYSTIKA® 75                                                           Pregabalin                                                                                        75 mg caps. x 28
Made in Argentina
For sale under prescriptiontacc-es
Pregabalin
Composition:
 Each capsule of Mystika 75 contains Pregabalin 75mg.
Therapeutic Action:
 Antiepileptic. Antineuralgic. Anxiolytic.
Indications:
 Treatment of neuropathic pain in adults. Adjunctive therapy for partial seizures with or without secondary generalization in adults. Treatment of generalized anxiety disorder in adults. Treatment of fibromyalgia.
Dosage and Administration
Orally, initially 150 mg per day. The dose may be increased to 300 mg daily. Maximum dose 600 mg per day.
Presentation:
 Mystika 75: packages containing 28 capsules.
 
             MYSTIKA® 150                                                         Pregabalin                                                                                        150 mg caps. x 28
Made in Argentina
For sale under prescriptiontacc-es
Pregabalin
Composition:
 Each capsule of Mystika 150 contains Pregabalin 150 mg.
Therapeutic Action:
 Antiepileptic. Antineuralgic. Anxiolytic.
Indications:
 Treatment of neuropathic pain in adults. Adjunctive therapy for partial seizures with or without secondary generalization in adults. Treatment of generalized anxiety disorder in adults. Treatment of fibromyalgia.
Dosage and Administration
Orally, initially 150 mg per day. The dose may be increased to 300 mg daily. Maximum dose 600 mg per day.
Presentation:
 Mystika 150: packs containing 28 capsules.
 
             PRILBEN® 10                                                           Memantine                                                                                        10 mg coat. tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Memantine
Composition:
 Each tablet of PRILBEN 10 contains 10 mg Memantine hydrochloride.
Therapeutic Action:
 Neuroprotective, neuroactive, modulator of glutamate.
Indications:
 Memantine is indicated for the symptomatic treatment of Alzheimer's dementia. Its effectiveness has been demonstrated in patients with moderate to severe Alzheimer's disease.
Dosage and Administration:
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. The diagnosis should be based on accepted diagnostic criteria (eg DSM IV). We recommend starting PRILBEN therapy only when a caregiver or family member is available to regularly monitor drug intake correctly. PRILBEN should be administered once a day, always at the same time. The tablets can be taken with or without food.
Adults / Dose Escalation:
 

The maximum daily dose is 20 mg per day. To reduce the risk of adverse effects, the maintenance dose is achieved by increasing the dose of 5 mg per week for the first 3 weeks as follows: Week 1 (days 1-7): The patient should take half a tablet of PRILBEN 10 (5 mg) daily for 7 days. Week 2 (days 8-14): The patient should take one tablet of PRILBEN 10 (10 mg) daily for 7 days. Week 3 (days 15-21): The patient should take a tablet and a half of PRILBEN 10 (15 mg) daily for 7 days. From Week 4: The patient should take one tablet of PRILBEN 20 (20 mg) daily. Maintenance Dose: The recommended maintenance dose is one tablet of PRILBEN 20 (20 mg) daily.

Renal impairment:
 

In patients with weakly affected renal function (serum creatinine up to 130 * mol / l), it is necessary to reduce the dose. In patients with moderate renal impairment (creatinine clearance 40-60 ml/min/1, 73m ²), the daily dose should be reduced to 10 mg / day. There is no data in patients with severe renal impairment.

Hepatic impairment:
 

No data are available the use of memantine in patients with liver failure.

Presentation:
 Packages containing 30 coated and slotted tablets of 10 mg.
 
             PRILBEN® 20                                                           Memantine                                                                                        20 mg coat. tabs. x 30
Industria Argentina
Venta Bajo Receta Archivadatacc-es
Memantina
Composición:
 Cada comprimido recubierto y ranurado de PRILBEN 20 contiene: Clorhidrato de memantina 20 mg.
Acción Terapéutica:
 Neuroprotector, neuroactivador, modulador del glutamato.
Indicaciones:
 Memantina está indicada para el tratamiento sintomático de la demencia tipo Alzheimer. Su eficacia ha sido demostrada en pacientes con enfermedad de Alzheimer moderada a severa.
Posología y Modo de administración:
El tratamiento debe ser iniciado y supervisado por un médico con experiencia en el diagnóstico y tratamiento de la demencia tipo Alzheimer. El diagnóstico debe estar basado en criterios diagnósticos aceptados (por ejemplo, DSM IV). Se recomienda iniciar la terapia con PRILBEN sólo cuando un cuidador o familiar esté disponible para monitorear regularmente la ingesta del fármaco en forma correcta. PRILBEN debe administrarse una vez al día, siempre a la misma hora. Los comprimidos recubiertos pueden tomarse con o sin alimentos.

Adultos / Escalado de dosis:
 

La dosis diaria máxima es de 20 mg al día. Para reducir el riesgo de sufrir efectos adversos, la dosis de mantenimiento se alcanza incrementando la dosis 5 mg cada semana durante las primeras 3 semanas de la siguiente manera: Semana 1 (días 1-7): el paciente debe tomar la mitad de un comprimido recubierto de PRILBEN 10 (5 mg) al día durante 7 días. Semana 2 (días 8-14): el paciente debe tomar un comprimido recubierto de PRILBEN 10 (10 mg) al día durante 7 días. Semana 3 (días 15-21): el paciente debe tomar un comprimido recubierto y medio de PRILBEN 10 (15 mg) al día durante 7 días. A partir de la semana 4: El paciente debe tomar un comprimido recubierto de PRILBEN 20 (20 mg) al día. Dosis de mantenimiento: La dosis recomendada de mantenimiento es un comprimido recubierto de PRILBEN 20 (20 mg) al día.


Insuficiencia renal:
 

En pacientes con función renal débilmente afectada (creatinina sérica de hasta 130*mol/l), no es necesario disminuir la dosis. En pacientes con insuficiencia renal moderada (clearence de creatinina 40-60 ml/min/1,73m²), la dosis diaria se debe reducir a 10 mg/día. No se dispone de datos en pacientes con insuficiencia renal grave.


Insuficiencia hepática:
 

No se dispone de datos del uso de memantina en pacientes con insuficiencia hepática.

Presentaciones:
 Envases conteniendo 30 comprimidos recubiertos y ranurados de 20 mg
             RENACENZ® (Importado)                                       Cerebrolysin                                                                                     2,152 mg/ml amp. x 10 ml x 5 
Made in Austria
For sale under prescription
Cerebrolysin
Composition:
 Each ml of RENACENZ contains: Cerebrolysin Concentrate (low molecular weight neuropeptides) 215.2 mg.
Therapeutic Action:
 Neurotrophic, neuroprotector.
Indications:
 Organic, metabolic and neurodegenerative disorders of the brain, especially Alzheimer-type senile dementia. Post apoplexy disorders. Cranium and cerebral trauma, post operative trauma, confusion or brain concussion.
Dosing and Mode of Administration:
Single doses of up to 50 ml may be administered. However, it is recommended to have a continuous treatment. The optimal and recommended duration of the treatment involves the daily administration over 10-12 days. Daily dose: For organic, metabolic disorder of the brain and neurodegenerative diseases (dementia) 5-30 ml. Post apoplexy disorders 10-50 ml. Cranium-brain trauma 10-50 ml. The effectiveness of the treatment may be increased by repeating cycles until the best therapeutic benefit is obtained. After the starting cycle, the frequency of doses may be reduced to 2 or 3 times a week. For each treatment cycle, the treatment must be discontinued during a cycle of the same duration than the duration of the treatment cycles. Doses of between 10 ml and up to a maximum of 50 ml are recommended only as slow IV infusion after dilution in the recommended standard solutions for perfusion. The perfusion duration must be between 15 and 60 minutes. Compatibility during 24 hours, at room temperature and in the presence of light has been demonstrated with the following standard perfusion solutions: - 0.9% sodium chloride (9 mg NaCl/ml), - Ringer Solution (Na + 153.98 mmol/l, Ca2+ 2.74 mmol/l, K+ 4.02 mmol/l, Cl- 163.48 mmol/l). - 5 % glucose. Vitamins and cardiovascular drugs may be administered concomitantly with RENACENZ, however these drugs must not be mixed in the same syringe.
Presentation:
 Packages containing five 10 ml ampoules. Keep at ambient temperature (no higher than 25ºC) and away from sources of light (in its package). Do not freeze. Open the ampoules only immediately prior to use.
             REVERTRIX® 5                                                        Olanzapine                                                                                        5 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescription
Olanzapine
Composition:
 Each tablet of REVERTRIX 5 contains Olanzapine 5 mg.
Therapeutic Action:
 Atypical antipsychotic (ATC Code: N05AH03), with low incidence of extrapyramidal effects and good efficacy against negative symptoms. Its blocking action has a high binding affinity for serotonin,dopaminergic, histaminergic and adrenergic receptors.
Indications:

Acute and chronic psychotic disorders, particularly in schizophrenia. Manic or mixed episodes of bipolar disorder. -->

Dosage and Administration:
Orally, once a day, with or without food.Starting dose: Adults 5-10 mg, adolescents 2.5 to 5 mg. It may be increased by 5 mg/day every 5-7 days up to a dose of 10 mg/day.
Presentation:
 Packages containing 30 coated and slotted tablets of 5 mg.
 
             REVERTRIX® 10                                                      Olanzapine                                                                                        10 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescription
Olanzapine
Composition:
 Each coated and slotted tablet of REVERTRIX 10 tablet contains Olanzapine 10 mg.
Therapeutic Action:
 Atypical antipsychotic (ATC Code: N05AH03), with low incidence of extrapyramidal effects and good efficacy against negative symptoms. Its blocking action has a high binding affinity for serotonin,dopaminergic, histaminergic and adrenergic receptors.
Indications:

Acute and chronic psychotic disorders, particularly in schizophrenia. Manic or mixed episodes of bipolar disorder. -->

Dosage and Administration:
Orally, once a day, with or without food.Starting dose: Adults 5-10 mg, adolescents 2.5 to 5 mg. It may be increased by 5 mg/day every 5-7 days up to a dose of 10 mg/day.
Presentation:
 Packages containing 30 coated and slotted tablets of 10 mg.
             SOSTEL® 20                                                            Paroxetine                                                                                         20 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Paroxetine
Composition:
 Each tablet contains Paroxetine 20 mg.
Therapeutic Action:
 Antidepressant
Indications:
 SOSTEL is indicated for the treatment of the major depressive disorder. Obsessive-compulsive disorder. Panic disorder with or without agoraphobia. Social anxiety disorder. Generalized anxiety disorder. Post traumatic stress disorder.
Mode of Administration:
It is advised to administer SOSTEL in a single daily take, with or without food intake, preferably in the morning.
Major depressive disorder:
 

Starting Dose: It is recommended to start with a 20 mg per day dose. Patients who are not responsive to this dose may find it beneficial to increase the dose by 10 mg/day up to a maximum of 50 mg per day. Dose changes must be made with intervals of at least one week. Maintenance Therapy: There is consensus that acute episodes of major depressive disorder require various months or more of drug treatment. Systemic evaluations of the efficacy of paroxetine showed that its efficacy is maintained over periods longer than a year with a dose of approximately 30 mg per day.

 
Obsessive-compulsive disorder (OCD):
 

Starting Dose: It is recommended to start with 20 mg per day, increasing by 10 mg/day at intervals of at least one week. The maximum dose must not exceed 60 mg per day. Maintenance Therapy: The recommended dose for OCD treatment is 40 mg per day. This disorder is a chronic condition, therefore, it is reasonable to consider continuing the treatment in a responsive patient. The dose must be adjusted to maintain the patient with the minimum effective dose. The dose must be periodically reassessed to determine the need to continue with the treatment.

 
Panic disorder with or without agoraphobia:
 

Starting Dose: It is recommended to start with 10 mg per day, increasing by 10 mg/day at intervals of at least one week. The maximum dose must not exceed 60 mg per day. Maintenance Therapy: the recommended dose is 40 mg per day. The panic disorder is a chronic condition, therefore, it is reasonable to consider continuing the treatment in a responsive patient. The dose must be adjusted to maintain the patient with the minimum effective dose. The dose must be periodically reassessed to determine the need to continue with the treatment.

 
Social Anxiety, Generalized Anxiety and Post Traumatic Stress Disorders:
 

Starting Dose: It is recommended to start with a 20 mg per day dose. Maintenance Therapy: the recommended dose is 20mg per day. It is advisable to re-evaluate the patient periodically to determine the lowest effective dose for maintenance, as well as the need to continue with the treatment.

 
Dosing in Elderly Populations, Debilitated Patients and Patients with Impairment of the Hepatic and/or Renal Function:
 

The recommended starting dose is 10 mg per day. The dose may be increased if prescribed. The dose must not exceed 40 mg per day.

Presentation:
 Packages containing 30 grooved, coated tablets.
 
             TALPRAM® 10                                                         Escitalopram                                                                                     10 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescription
Escitalopram
Composition:
 Each coated tablet of TALPRAM 10 contains Escitalopram Oxalate (equivalent to 10 mg. Escitalopram) 12.770 mg.
Therapeutic Action:
 Antidepressant (Classification ATC N06 AB).
Indications:

(according to DSM IV): Antidepressant. Treatment of Major Depressive Disorder and maintenance to prevent relapse. Treatment of anxiety disorders (panic disorder) with or without agoraphobia. Treatment of social phobia. Treatment of generalized anxiety disorder. -->

Mode of Administration:
TALPRAM is given once daily and can be taken with or without food.
Dosage:
The usual daily dose for Major Depressive Disorder, Generalized Anxiety and Social Phobia is 10 mg. For Anxiety Disorder is 5 mg. in the first week and then 10 mg. The maximum daily dose for all indications is 20 mg. 
Elderly patients (> 65 years of age):
 

We should consider initiating treatment with half the usually recommended dose and a lower maximum dose.

 
Children and adolescents (<18 years):
 

Escitalopram is not recommended in children and adolescents under 18 years, as safety and efficacy has not been established in this population.

 
Patients with Renal Insufficiency:
 

No need for dose adjustment in patients with mild or moderate renal insufficiency. Administration with caution is advised in patients with severely impaired renal function (creatinine clearance <30 ml / min).

 
Patients with Hepatic Insufficiency:
 

It is recommended a starting dose of 5 mg during the first 2 weeks of treatment. According to the individual patient's response, the dose can be increased to 10 mg. Discontinuation of treatment: When Escitalopram should be discontinued, the dose should be reduced gradually over a period of one to two weeks to avoid possible withdrawal reactions.

Presentation:
 Packages containing 30 coated tablets.
 
             TALPRAM® 20                                                         Escitalopram                                                                                     20 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescription
Escitalopram
Composition:
 Each coated tablet of TALPRAM 20 contains Escitalopram Oxalate (equivalent to 20 mg. Escitalopram) 25.540 mg.
Therapeutic Action:
 Antidepressant (Classification ATC N06 AB).
Indications:

(according to DSM IV): Antidepressant. Treatment of Major Depressive Disorder and maintenance to prevent relapse. Treatment of anxiety disorders (panic disorder) with or without agoraphobia. Treatment of social phobia. Treatment of generalized anxiety disorder. -->

Mode of Administration:
TALPRAM is given once daily and can be taken with or without food.
Dosage:
The usual daily dose for Major Depressive Disorder, Generalized Anxiety and Social Phobia is 10 mg. For Anxiety Disorder is 5 mg. in the first week and then 10 mg. The maximum daily dose for all indications is 20 mg. 
Elderly patients (> 65 years of age):
 

We should consider initiating treatment with half the usually recommended dose and a lower maximum dose.

 
Children and adolescents (<18 years):
 

Escitalopram is not recommended in children and adolescents under 18 years, as safety and efficacy has not been established in this population.

 
Patients with Renal Insufficiency:
 

No need for dose adjustment in patients with mild or moderate renal insufficiency. Administration with caution is advised in patients with severely impaired renal function (creatinine clearance <30 ml / min).

 
Patients with Hepatic Insufficiency:
 

It is recommended a starting dose of 5 mg during the first 2 weeks of treatment. According to the individual patient's response, the dose can be increased to 10 mg. Discontinuation of treatment: When Escitalopram should be discontinued, the dose should be reduced gradually over a period of one to two weeks to avoid possible withdrawal reactions.

Presentation:
 Packages containing 10 and 30 coated tablets.
             TIONEUROL® 600                                                   Thioctic Acid                                                                                     600 mg coat. tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Thioctic Acid
Composition:
 Each TIONEUROL 600 tablet contains: Thiotic acid 600 mg.
Therapeutic Action:
 Central and peripheral neuroprotector. Cellular antioxidant.
Indications:
 Central and peripheral neuropathies, especially caused by diabetes.
Dosing and Administration:
One tablet a day, taken whole (not to be chewed) with liquids, and preferably half an hour before breakfast.
Presentation:
 Packages containing thirty 600 mg coated tablets.
 
             VECETAM® 500                                                       Levetiracetam                                                                                   500 mg coat. tabs. x 60
Made in Argentina
For sale under prescriptiontacc-es
Levetiracetam
Composition:
 Each tablet of VECETAM 500 contains 500 mg.
Therapeutic Action:
 Anticonvulsant.
Indications:

Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients over 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy: - In the treatment of partial onset seizures with or without secondary generalization in adults and children over 4 years with epilepsy. - In the treatment of myoclonic seizures in adults and adolescents over 12 years with juvenile myoclonic epilepsy. - In the treatment of tonic-clonic seizures in adults and adolescents primaries over 12 years with idiopathic generalized epilepsy.

Dosing and Administration:
The tablets should be taken with sufficient liquid and can be taken with or without meals. The daily dose is administered in two equally divided doses. 
Monotherapy - Adults and adolescents over 16 years:
 

The recommended starting dose is 250 mg twice a day, which must be increased to the therapeutic dose of 500 mg twice daily after two weeks of treatment. The dose may be increased depending on clinical response with 250 mg twice a day every 2 weeks. The maximum dose is 1500 mg twice a day.

 
Concomitant therapy - Use in adults (18 years) and adolescents (12 to 17 years) weighing 50 kg or more:
 

The initial therapeutic dose is 500 mg twice a day. This dose can be started from the first day of treatment. Depending on clinical response and tolerability, the daily dose can be increased to 1500 mg twice a day. The dose modification can be performed with increases or reductions of 500 mg twice daily every two to four weeks.

 
Use in elderly (65 years and older):
 

Dosage adjustment is recommended in elderly patients with compromised renal function.

 
Use in children between 4 and 11 years of age and adolescents (12 to 17 years) weighing less than 50 kg:
 

The initial therapeutic dose is 10 mg / kg twice a day. Depending on clinical response and tolerability, the dose can be increased to 30 mg / kg twice a day. Dose changes should not exceed increases / decreases of 10 mg / kg twice daily every two weeks. You should use the lowest effective dose. The dosage for children weighing 50 kg or more is the same as in adults. The physician should prescribe the most appropriate concentration according to weight and dose.

 
Use in children younger than 4 years:
 

Levetiracetam is not recommended for use in children under 4 years due to insufficient data on safety and efficacy.

Presentation:
 VECETAM 500: Packages containing 60 tablets.
 
             VECETAM® 1000                                                     Levetiracetam                                                                                   1000 mg coat. tabs. x 30
Made in Argentina
For sale under prescriptiontacc-es
Levetiracetam
Composition:
 Each coated tablet contains 1000 VECETAM Levetiracetam 1000 mg.
Therapeutic Action:
 Anticonvulsant.
Indications:

Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients over 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy: - In the treatment of partial onset seizures with or without secondary generalization in adults and children over 4 years with epilepsy. - In the treatment of myoclonic seizures in adults and adolescents over 12 years with juvenile myoclonic epilepsy. - In the treatment of tonic-clonic seizures in adults and adolescents primaries over 12 years with idiopathic generalized epilepsy.

Dosing and Administration:
The tablets should be taken with sufficient liquid and can be taken with or without meals. The daily dose is administered in two equally divided doses. 
Monotherapy - Adults and adolescents over 16 years:
 

The recommended starting dose is 250 mg twice a day, which must be increased to the therapeutic dose of 500 mg twice daily after two weeks of treatment. The dose may be increased depending on clinical response with 250 mg twice a day every 2 weeks. The maximum dose is 1500 mg twice a day.

 
Concomitant therapy - Use in adults (18 years) and adolescents (12 to 17 years) weighing 50 kg or more:
 

The initial therapeutic dose is 500 mg twice a day. This dose can be started from the first day of treatment. Depending on clinical response and tolerability, the daily dose can be increased to 1500 mg twice a day. The dose modification can be performed with increases or reductions of 500 mg twice daily every two to four weeks.

 
Use in elderly (65 years and older):
 

Dosage adjustment is recommended in elderly patients with compromised renal function.

 
Use in children between 4 and 11 years of age and adolescents (12 to 17 years) weighing less than 50 kg:
 

The initial therapeutic dose is 10 mg / kg twice a day. Depending on clinical response and tolerability, the dose can be increased to 30 mg / kg twice a day. Dose changes should not exceed increases / decreases of 10 mg / kg twice daily every two weeks. You should use the lowest effective dose. The dosage for children weighing 50 kg or more is the same as in adults. The physician should prescribe the most appropriate concentration according to weight and dose.

 
Use in children younger than 4 years:
 

Levetiracetam is not recommended for use in children under 4 years due to insufficient data on safety and efficacy.

Presentation:
 VECETAM 1000: Packages containing 30 tablets.
 
             ZOLODORM®                                                          Zolpidem                                                                                            10 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Zolpidem
Composition:
 Each coated tablet contains: Zolpidem Hemitartrate 10 mg.
Therapeutic Action:
 Hypnotic.
Indications:
 Short term treatment of the sleeping disorder (DSM IV)
Dosing and Administration:
The treatment with Zolpiderm must be patient-specific. The usual dose for the treatment of insomnia is 10 mg administered orally immediately before going to bed. The therapy must be restricted from 7 to 10 days. The patient must be evaluated if it is necessary to continue with the treatment for more than 2 or 3 weeks. It may be necessary to decrease the dose when zolpiderm is administered in combination with CNS depressor drugs, due to the possibility of additive effects.
Presentation:
 Package containing 30 coated tablets.
 

Note: Products which are still under patent are manufactured according to Argentinean requirements. Please note that they are delivered only to countries where the substance and  its use are not protected by patents.